Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
28 November 2023 - 12:00AM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced that it will share
STAR-0215 Phase 1a results in an encore presentation at the annual
World Allergy Congress on Sunday, December 3 at 10:00am ICT in
Bangkok, Thailand.
Chris Morabito, M.D., Chief Medical Officer at Astria
Therapeutics, will present a poster titled, “Support for STAR-0215
Administered Every Three- or Six-Months for Hereditary Angioedema:
Phase 1a Results,” at 10:00am ICT on December 3 in Convention Hall
B, poster board number 246.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
About STAR-0215:
STAR-0215 is a monoclonal antibody inhibitor of plasma
kallikrein in development for the treatment of HAE. Our vision is
for STAR-0215 to be the first-choice preventative treatment for
people with HAE dosed once every three and six months and to make
substantial progress towards normalizing their lives. The Phase
1b/2 ALPHA-STAR trial evaluating STAR-0215 in HAE patients is
ongoing, with proof-of-concept results expected in the first
quarter of 2024.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of applicable securities laws and regulations
including, but not limited to, statements regarding: our
expectations regarding the timing of proof-of-concept results from
the Phase 1b/2 ALPHA-STAR trial of STAR-0215; our vision and goals
for STAR-0215 as a potential treatment for HAE; and our goal to
bring life-changing therapies to patients and families affected by
allergic and immunological diseases. The use of words such as, but
not limited to, “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would,” or "vision," and similar words expressions are intended to
identify forward-looking statements. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based on Astria’s current beliefs, expectations
and assumptions regarding the future of its business, future plans
and strategies, future financial performance, results of
pre-clinical and clinical results of the Astria’s product
candidates and other future conditions. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the following
risks and uncertainties: changes in applicable laws or regulations;
the possibility that we may be adversely affected by other
economic, business, and/or competitive factors; risks inherent in
pharmaceutical research and development, such as: adverse results
in our drug discovery, preclinical and clinical development
activities, the risk that the results of preclinical studies may
not be replicated in clinical trials, that the preliminary or
interim results from clinical trials may not be indicative of the
final results, that the results of early stage clinical trials,
such as the results from the Phase 1a clinical trial, may not be
replicated in later stage clinical trials, including the ALPHA-STAR
trial, the risk that we may not be able to enroll sufficient
patients in our clinical trials on a timely basis, and the risk
that any of our clinical trials may not commence, continue or be
completed on time, or at all; decisions made by, and feedback
received from, the U.S. Food and Drug Administration and other
regulatory authorities on our regulatory and clinical trial
submissions and other feedback from potential clinical trial sites,
including investigational review boards at such sites, and other
review bodies with respect to STAR-0215, STAR-0310, and any other
future development candidates; our ability to manufacture
sufficient quantities of drug substance and drug product for
STAR-0215, STAR-0310, and any other future product candidates on a
cost-effective and timely basis, and to develop dosages and
formulation for STAR-0215, STAR-0310, and any other future product
candidates that are patient-friendly and competitive; our ability
to develop biomarker and other assays, along with the testing
protocols therefore; our ability to obtain, maintain and enforce
intellectual property rights for STAR-0215, STAR-0310, and any
other future product candidates; our potential dependence on
collaboration partners; competition with respect to STAR-0215,
STAR-0310, or any of our other future product candidates; the risk
that survey results and market research may not be accurate
predictors of the commercial landscape for HAE, the ability of
STAR-0215 to compete in HAE and the anticipated position and
attributes of STAR-0215 in HAE based on clinical data to date, its
preclinical profile, pharmacokinetic modeling, market research and
other data; risks that any of our clinical trials of STAR-0310 may
not commence, continue or be completed on time, or at all; risks
that results of preclinical studies of STAR-0310 will not be
replicated in clinical trials; risks with respect to the ability of
STAR-0310 to compete in AD and the anticipated position and
attributes of STAR-0310 in AD based on its preclinical profile; our
ability to manage our cash usage and the possibility of unexpected
cash expenditures; our ability to obtain necessary financing to
conduct our planned activities and to manage unplanned cash
requirements; the risks and uncertainties related to our ability to
recognize the benefits of any additional acquisitions, licenses or
similar transactions; and general economic and market conditions;
as well as the risks and uncertainties discussed in the “Risk
Factors” section of our Quarterly Report on Form 10-Q for the
period ended September 30, 2023 and in other filings that we may
make with the Securities and Exchange Commission. New risks and
uncertainties may emerge from time to time, and it is not possible
to predict all risks and uncertainties. Astria may not actually
achieve the forecasts or expectations disclosed in our
forward-looking statements, and investors and potential investors
should not place undue reliance on Astria’s forward-looking
statements. Neither Astria, nor its affiliates, advisors or
representatives, undertake any obligation to publicly update or
revise any forward-looking statement, whether as result of new
information, future events or otherwise, except as required by law.
These forward-looking statements should not be relied upon as
representing Astria’s views as of any date subsequent to the date
hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231127875051/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Apr 2024 to May 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From May 2023 to May 2024